Evidence map›Paper›PMID 40657252›Full record

ArticleFrontiers in oncology2025

Investigating the link between

Baha Sharaf, Hira Bani Hani, Anas Zayed, Maha Barbar, Suhaib Khater, Ahmad Hushki, Rashid Abdel-Razeq, Mohammad Titi, Reem Al-Halalsheh, Suleiman Mahafdah and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Baha SharafDepartment of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Hira Bani HaniDepartment of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Anas ZayedDepartment of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Maha BarbarDepartment of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Suhaib KhaterDepartment of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Ahmad HushkiDepartment of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Rashid Abdel-RazeqDepartment of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Mohammad TitiDepartment of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Reem Al-HalalshehDepartment of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Suleiman MahafdahDepartment of Surgery, Royal Jordanian Medical Services, Amman, Jordan.
Lin AshourDepartment of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.
Hikmat Abdel-RazeqDepartment of Internal Medicine, King Hussein Cancer Center, Amman, Jordan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Methods: All newly diagnosed patients with solid tumors were offered participation in a universal germline genetic screening study utilizing an investigational 84-gene panel. Patients were categorized based on whether they met or did not meet the criteria outlined in the National Comprehensive Cancer Network (NCCN) for genetic testing. Results: Among the screened cancer patients ( Discussion: These findings suggest that Arab individuals with the

Indexed as

APCAPCI1307Kbreast cancercolon cancergermline genetic testinghereditary cancer

Identifiers

PMID40657252
PMCPMC12245844

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.